An exchange traded fund (ETF) is a type of security that involves a collection of securities—such as stocks—that often tracks an underlying index, although they can invest in any number of industry sectors or use various strategies.
One ETF in particular that tracks biotech’s is the SPDR S&P Biotech ETF (NYSE: XBI) XBI equal weights its portfolio…which provides greater emphasis on the smaller names in the index.
XBI contains names such as Biogen, Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Gilead Sciences, (NASDAQ: GILD), and Moderna, Inc. (NASDAQ: MRNA) among others.
XBI bottomed mid-March 2020 and recovered to a new high in July. But the question is, where do we go from here?
As you can see, XBI has touched the 108 mark not once, not twice, but three times at the time of writing. But even water can penetrate rock – if enough drops fall on it.
With Covid-19 vaccines front and center in the gains in the XBI, it’s a race to the finish and the winner could thrash the rest of index companies vying for the prize.
So, if you’re looking to deploy capital in the medical space, you might consider diversifying. The Centers for Disease Control and Prevention has long considered diabetes to be an epidemic. Take a look at the diabetic/adult nutrition & medical foods sector.
The diabetic/adult nutrition & medical foods sector dominated by giants like Nestle (OTC: NSRGY) and Abbott Labs (NYSE: ABT). But there is a pure play in the space with a very compelling story, Glucose Health, Inc. (OTC Pink: GLUC).
Glucose Health, Inc. manufacturers nutritional beverages for the diabetic-adult nutrition category under the registered trademark GLUCODOWN®. This GLUCODOWN® product is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain healthy blood sugar levels and digestive health.
And, here is the best part. The GLUCODOWN® brand has made its way onto the shelves of the nation’s biggest pharmacy chains, right beside the diabetic nutrition products from Nestle and Abbott, and as well online at Amazon.com (NASDAQ: AMZN) – yet is still trading below a $20 million valuation!
Glucose Health, Inc. (OTC Pink: GLUC) just reported unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.
What are the revenues of this company going to look like when the latest GLUCODOWN® sales numbers are reported for Q3 and Q4?
Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetes space and should be on everybody’s watch list.
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.